Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Taking the drug made one writer feel so sick she quit and focused on healthy habits instead of her body size. Turns out, 65% ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

I n an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the ...